Sunovion's schizophrenia drug Latuda approved for use in teens

A schizophrenia drug developed by Marlborough-based Sunovion Pharmaceuticals has been granted wider approval by the FDA. The company said in a statement on Saturday that its drug, Latuda, had been approved by the FDA to treat adolescents aged 13 to 17. Previously, the drug had been approved only for adults suffering from schizophrenia or major depressive episodes associated with bipolar disorder. Sunovion is one of the largest privately-held life science companies headquartered in Massachusetts,…
Source: bizjournals.com Health Care:Physician Practices headlines - Category: American Health Authors: Source Type: news